Jordi Remon

In NSCLC & AGA we usually use the ⬆️ dose of targeted therapies despite no always correlation btw dose and efficacy or intracranial activity.In this review, we discuss these topics. Is time to redefine doses of TT as now applied across stages? doi.org/10.1016/j.ctrv…

Qx raise about role of ADCs in NSCLC. Data in NSCLC and AGA🧬most in mEGFR at osimertinib. but should be applied as monotherapy? With osimertinib? Some data in NSCLC with other AGA but no intracranial data. There is a room for improvement. We need to define the population

More data supports KRASi + IO in 1L NSCLC with mKRAS G12C. Today: olomorasib+pembro with high ORR regardless PDL1. (Adagrasib+pembro ⬆️activity in PDL1>50%) Hwvr, how comut (STK11/KEAP1) impact the efficacy of these combos? Should we add Chemo when exist comut at baseline?#ASCO25

Sequential ttx with zipalertinib after amiv is feasible in pts with EGFRex20ins 🫁. Hwr,this agent is tested in 1stL in combo with CT. Best ttx: CT-Ami —> TKI vs TKI +\_CT —> Ami —> CT?. It’s not the strongest the first, it’s the all sequence treatment that impacts OS #ASCO25

AntiPd1 Benmelostat + anlotinin improved PFS vs pembro in 1st L 🫁 all PDL1. But Pembro alone is not the SoC in 1st L.Benefit mainly driven by high PDL1. Is benmel + anlotinib > ivonescimab (bispecific Pd1/VEGFR)?Data suggestIO+antiangiogenic is appropriate in 1st L hPDL1.#ASCO25

More is really better for all?: Dato-Dxd+pembro+/-chemo in 1st L 🫁. TROP2 NMR is a predictive bmk to enrich population who may benefit the of adding this ADC but small sample size, and QoL of this intensive treatment? Do we need maintenance DatoDxd + Pembro? Too much…#ASCO25

Pembro +adagrasib in KRAS G12C NSCLC all comers in 1st L. Outcome in all PDL1 strata mirroring CT+IO. Can we spare chemo in these pts regardless of PDL1 expression or just for high PDL1?Better outcomes with chemo-adagrasib-pembro but higher tox? IcORR? #ASCO25

BL-B01D1 bispecific ADC anti EGFR xHER3. Ph1 trial in 🫁 with genomic alt other than common EGFRm. ORR 46%. PFS 7 mo. Despite limited sample in each cohort, data suggest activity of this ADC in NSCLC with AGAs. Pending to improve tox profile (80% G3 TRAEs). icORR? #ASCO25

DB-1310 is a new ADC anti-HER3 with pantumor activity including NSCLC with promising activity in EGFRm 🫁. Based on disappointing results with HERTHENALung trial, next step should be DB-1310 + osimertinib in osimertinib-PD disease? #ASCO25

Cooperative Academic groups like #EORTC Lung Cancer Group are amazing!We have made our Spring meeting in Genova 🇮🇹with an outstanding group of Young Investigators 👏🏻.Lots ideas for future academic trials to ⬆️outcome of pts with 🫁 cancers. Working Together makes us stronger💪🏻

After atezolizumab subcutaneous we have Pembrolizumab sc that is not inferior to pembrolizumab iv in 1st line in aNSCLC. Hwr, do we need this sc formulation every 6 weeks? New option on daily practice but what about price? #ELCC2025

Adagrasib 400 mg + Pembrolizumab impressive mPFS in KRAS G12C mutant NSCLC and PDL1 >50% and good safety. Better than IO or CT+IO alone. Good chemo free strategy for patients Await for ph3 trial. #ELCC2025

We had efficacy data ADCs after osi-PD in EGFRm NSCLC. Today good mPFS (9.5-11.7) with Osi+DatopotamAb Dxd after osi-PD. Data looks ➕promising than chemo+Amiv. Better 🧠 protection maintaining osi? Biomarker for dato? Toxicity is imp. Future trial: osi-DATOD vs Ami-CT? #ELCC25

BAY2927088 a TKI antiHER2 ⬆️activity in HER2naive and HER2-pretxt pts with HER2m.3 ongoing ph3 in 1st L (T-Dxd, BAY2927088, zongertinib) vs CT-IO What will be winner 🤷🏻‍♂️?Important to look across trials: mPFS,🧠activity,side-effects.Role for T-Dxd+TKI antiHER2? Sequential? #ELCC25

Personalised approach at osimertinib PD with savolitinib and osimertinib in MET deregulated EGFRm NSCLC looks promising. Is it better than CT+Ami or ADC? Hwr, it is a chemofree strategy and other treatments could be applied later #ELCC25

IO has changed ttx and outcome in adv 🫁.It’s time that Academic trials (PULSE @BenjaminBesseMD )and international grants test IO de-escalation to ensure ➕ pts receive these drugs, ⬆️outcomes to more pts worldwide, while ⬇️financial tox.Thk all authors!👏🏻 ascopubs.org/doi/10.1200/JC…

🎺TelisoV+Osi potential ttx in MET overex meta EGFRm NSCLC with osi resist disease 👏🏻. Hw: ✏️Other ADCs with activity ✏️Not easy tissue Bx at PD for testing MET ✏️New 1stL options may ⬇️ MET expression at PD? ✏️🧠 activity @stephanieplsaw @HHorinouchi doi.org/10.1016/j.anno…

Inspired by my good friend and slide master @JordiRemon - sharing these updated summary slides for 1L and post-progression treatment options for advanced stage EGFR-mutated NSCLC. Might be outdated soon but hopefully not before 2025 😬 @OncoAlert